FDA Grants Orphan Drug Designation to Amphix Bio’s Spinal Cord Injury Treatment
Amphix Bio, an innovative pre-clinical stage biotechnology company, has announced that its lead therapeutic candidate, AMFX-200, has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of acute spinal cord injury (SCI). This condition, which…